93 related articles for article (PubMed ID: 32274876)
1. Disparities between Antibody Occupancy, Orientation, and Cytotoxicity in Immunotherapy.
Ta AN; Tennyson RL; Aceveda DC; McNaughton BR
Chembiochem; 2020 Sep; 21(17):2435-2439. PubMed ID: 32274876
[TBL] [Abstract][Full Text] [Related]
2. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
Fuenmayor J; Perez-Vazquez K; Perez-Witzke D; Penichet ML; Montano RF
Mol Cancer Ther; 2010 Aug; 9(8):2175-85. PubMed ID: 20682652
[TBL] [Abstract][Full Text] [Related]
3. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
[TBL] [Abstract][Full Text] [Related]
4. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
[TBL] [Abstract][Full Text] [Related]
5. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
6. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering.
D'Eall C; Pon RA; Rossotti MA; Krahn N; Spearman M; Callaghan D; van Faassen H; Hussack G; Stetefeld J; Butler M; Durocher Y; Zhang J; Henry KA; Tanha J
Immunol Cell Biol; 2019 Jul; 97(6):526-537. PubMed ID: 30680791
[TBL] [Abstract][Full Text] [Related]
7. A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.
Gray MA; Tao RN; DePorter SM; Spiegel DA; McNaughton BR
Chembiochem; 2016 Jan; 17(2):155-8. PubMed ID: 26556305
[TBL] [Abstract][Full Text] [Related]
8. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
9. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
10. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
Amiri MM; Golsaz-Shirazi F; Soltantoyeh T; Hosseini-Ghatar R; Bahadori T; Khoshnoodi J; Navabi SS; Farid S; Karimi-Jafari MH; Jeddi-Tehrani M; Shokri F
Invest New Drugs; 2018 Apr; 36(2):171-186. PubMed ID: 28983766
[TBL] [Abstract][Full Text] [Related]
11. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
13. Charge variant analysis of proposed biosimilar to Trastuzumab.
Dakshinamurthy P; Mukunda P; Prasad Kodaganti B; Shenoy BR; Natarajan B; Maliwalave A; Halan V; Murugesan S; Maity S
Biologicals; 2017 Mar; 46():46-56. PubMed ID: 28087106
[TBL] [Abstract][Full Text] [Related]
14. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Deng W; Liu J; Pan H; Li L; Zhou C; Wang X; Shu R; Dong B; Cao D; Li Q; Wang Z
J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
[TBL] [Abstract][Full Text] [Related]
15. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
[TBL] [Abstract][Full Text] [Related]
16. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
17. Development and characterization of a fully functional small anti-HER2 antibody.
Gao J; Li B; Li H; Zhang X; Zhang D; Zhao L; Wang C; Fang C; Qian W; Hou S; Kou G; Wei H; Shi S; Wang H; Guo Y
BMB Rep; 2009 Oct; 42(10):636-41. PubMed ID: 19874707
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
19. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
[TBL] [Abstract][Full Text] [Related]
20. Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer.
Masuda T; Fujimoto H; Teranaka R; Kuroda M; Aoyagi Y; Nagashima T; Sangai T; Takada M; Nakagawa A; Kubota Y; Yokote K; Ohtsuka M
Breast Cancer Res Treat; 2020 Apr; 180(3):625-634. PubMed ID: 32124135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
